Following treatment with anti-PD-1/PD-L1 antibodies, macrophages depict enhanced phagocytic activity and activation, thereby reinstating their anti-tumor function, which is a crucial component of innate immunity. This evidence concerns the gene PDCD1 and neoplasm.